Head & Neck Cancers

Dr. Ezra Cohen, from the University of Chicago, Discusses Treating Medullary Thyroid Cancer

Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

The use of PET/CT scans in the detection of early recurrence in patients with squamous cell carcinoma of the head and neck remains an open question, despite recent research suggesting beneficial results.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

US investigators have found that suicide rates in recent years have significantly increased in patients with oral cavity and oropharyngeal cancer.

Erin McMenamin, MSN, from the Hospital of the University of Pennsylvania, on HPV-related Head & Neck Cancer Prognosis

Treatment of head and neck cancer often leaves patients with aftereffects that are bothersome at the very least and life-altering at their worst.

Minimally invasive transoral robotic surgery, used alone or combined with adjuvant therapy, provides good functional and oncologic outcomes in patients with oropharyngeal squamous cell carcinoma.

Dr. Eric Sherman, from Memorial Sloan-Kettering Cancer Center, Discusses Vandetanib's Dosage and Precautions

A retrospective analysis of the risks of hypothyroidism in patients who received sunitinib and sorafenib is gaining attention in the field of head and neck cancers.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Patients with oropharyngeal squamous cell carcinoma who had matted lymph nodes -- nodes that are connected together -- are more likely to metastasize than those without matted lymph nodes.

Approximately 7% of Americans are infected with oral human papillomavirus (HPV), and men are 3 times as likely to be infected as women.

Acupuncture may help prevent xerostomia in patients with nasopharyngeal carcinoma undergoing radiotherapy and may also reduce symptom severity.

Researchers are dissecting new studies regarding targeted therapies as well as combined therapeutic approaches for HPV in the progression of head and neck cancers.

Researchers are reporting favorable early results with the addition of bevacizumab to conventional chemoradiation in patients with advanced nasopharyngeal cancer.

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Human papillomavirus is perhaps best known as the main cause of cervical cancer, but if recent trends continue, by 2020 HPV will cause more cases of oropharyngeal cancer each year than cervical cancer.

Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.

Approximately 7% of Americans carry the human papillomavirus (HPV) in their oral cavities, and men are 3 times more likely to carry the virus than women.

In an era when advances in chemoradiation and targeted therapies have revolutionized treatment in head and neck oncology patients, it's possible that treating physicians might not know where surgery fits into the regimen.

Dr. Barbara Burtness, from Fox Chase Cancer Center, on the 2 Types of Head and Neck Cancer